An Investigation into the role of Matrix Metalloproteinases (MMPs) in Lower Limb Vascular Restenosis

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2006
INTERVENTION: Patients under the care of the Cambridge Vascular Unit undergoing femoro‐popliteal angioplasty or femoro‐popliteal/tibial bypass will be eligible for the study. The indication for intervention will be severe limb ischaemia (rest pain, ulceration, gangrene) or short distance claudication failing to respond to medical and exercise therapy. Pre‐procedural Noninvasive Assessments: Following informed consent the degree of ischaemia will be measured using ankle brachial pressure index (ABPI) measurements and transcutaneous oxygen measurements (TcPO2). Arterial stiffness and Endothelial Function will also be determined by applying a pressure probe to the carotid and radial arteries in turn with concomitant ECG gating. Percutaneous Angioplasty: These procedures are routinely carried out as either day cases or with overnight stay. During the procedure two 40 ml blood samples will be taken for plasma MMP analysis, plus CRP level, cholesterol, U&Es, elastin breakdown products, elastase activity and genetic analyses. One 40 ml sample will be systemic venous blood taken from the venous access cannula inserted for the procedure. A second 40 ml sample will be taken from the femoral vein in the leg undergoing the procedure. This is blood returning from the treated leg, and is more likely to reflect the local MMP activity potentially related to restenosis. On the same day as the PTA procedure the patients will be commenced on the SDD/placebo medication in a double blind randomised design. One tablet (25 mgs SDD) twice per day. This will be continued for 24 weeks post procedure. Post Procedure Follow Up: Colour duplex ultrasound assessment of the angioplasty site will be used to document blood velocities across the lesion and percentage of restenosis. These measurement will take place in the Vascular Laboratory at the following intervals: 1, 6, 12, 24, 36, 52 weeks. At 24 and 52 weeks repeat blood samples will be taken. Femoro‐distal bypass: The same pre‐procedural assessments CONDITION: Surgery: Cardiovascular ; Surgery ; Cardiovascular PRIMARY OUTCOME: 1. MMP activities SDD versus placebo; 2. CRP levels; 3. Endothelial function and re‐stenosis; 4. Arterial wall stiffness and re‐stenosis. SECONDARY OUTCOME: Not provided at time of registration INCLUSION CRITERIA: Serum samples collected at the time of vascular intervention (radiologist or surgeon). Follow up samples by vascular research fellow. Arterial wall and vein biopsies taken at the time of surgery by operating surgeon.
Epistemonikos ID: d319e6f635665b989ff25e0944c5ee07b3ead3a6
First added on: Aug 21, 2024